A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Hoffmann-La Roche
Hoffmann-La Roche
Fate Therapeutics
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)